GSK: progress report at IDWeek
(CercleFinance.com) - GSK and ViiV Healthcare will be presenting scientific progress in their leading infectious diseases portfolio at IDWeek 2023 from 11 to 15 October.
A total of 47 abstracts will be presented covering scientific developments in a range of infectious diseases, including seasonal respiratory viruses, HIV and chronic viral infections, affecting large patient populations.
Eleven abstracts have been accepted from GSK's world-leading vaccine portfolio, including the first scientific presentation of efficacy and safety data for the respiratory syncytial virus (RSV) vaccine over two full seasons.
A further 23 abstracts will be presented by ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer, Inc. and Shionogi & Co, Ltd. as shareholders, advancing knowledge in the areas of treatment, prevention and improved care for specific patient populations.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
A total of 47 abstracts will be presented covering scientific developments in a range of infectious diseases, including seasonal respiratory viruses, HIV and chronic viral infections, affecting large patient populations.
Eleven abstracts have been accepted from GSK's world-leading vaccine portfolio, including the first scientific presentation of efficacy and safety data for the respiratory syncytial virus (RSV) vaccine over two full seasons.
A further 23 abstracts will be presented by ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer, Inc. and Shionogi & Co, Ltd. as shareholders, advancing knowledge in the areas of treatment, prevention and improved care for specific patient populations.
Copyright (c) 2023 CercleFinance.com. All rights reserved.